Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone + ondansetron
- Development stage
- Preclinical
- Lead developer
- Adial Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of naltrexone (a mu opioid antagonist) and ondansetron (a 5-HT3 antagonist) that has been studied for the treatment of alcohol dependence, particularly in early-onset alcoholics (EOA). The combination appears to work synergistically to reduce alcohol consumption and craving by targeting different neurotransmitter systems involved in alcohol reward.
- Other names
- Naltrexone/ondansetron
02
Targets
HTR3A (5-hydroxytryptamine receptor 3A)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on naltrexone + ondansetron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone + ondansetron.